- Final analysis of
the pharmacokinetic study confirms that water soluble and solvent free
Paclical and US-market approved Abraxane have nearly identical
concentration curves of both total and unbound paclitaxel following
intravenous infusion of 260mg/m2 suggesting the same efficacy of the two drugs
Oasmia Pharmaceutical AB (OASM),
confirmed today the previously published findings from a head-to-head
comparison study of its lead human cancer product Paclical and Celgene's
Abraxane, demonstrated superimposable paclitaxel PK profiles. The study
was conducted in women with metastatic breast cancer.
"The
present cross-over study of Paclical and Abraxane demonstrating
virtually identical plasma levels of total and unbound drugs for the two
formulations," stated Olof Borgå, PhD, pharmacokinetic expert.
"Statistical analysis demonstrated the two formulations to be
bioequivalent with regard to drug concentrations. The bioequivalence
demonstrated for unbound paclitaxel is of particular importance, since
it is this concentration that is related to clinical effects. Also, the
ratio between unbound and total drug showed bioequivalence."
Oasmia believes that results
from this study strengthen its position for rapid growth among
competitors within the oncology sector, including Celgene Corporation
and Sorrento Therapeutics, Inc. In 2014, Abraxane generated total net
sales of $947 million, a 28 percent increase from the prior year.
Further, Sorrento Therapeutics expanded its Cynviloq strategy into
multiple cancer indications, potentially receiving over $1 billion
compensation for rights.
"We
are pleased that the final study data reflects the optimism many in the
pharmaceutical industry have displayed regarding Paclical's potential
and its role as a key branded player in the oncology sector", said
Julian Aleksov, Executive Chairman of Oasima Pharmaceutical AB.
"Abraxane is the current taxane market leader in the United States, and
we have now clearly demonstrated that Paclical is at least an equal but
with a more cost effective nanoparticle technology."
About Oasmia Pharmaceutical AB
Oasmia
Pharmaceutical AB develops new generations of drugs in the field of
human and veterinary oncology. The company's product development aims to
create and manufacture novel nanoparticle formulations and
drug-delivery systems based on well-established cytostatics which, in
comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. Oasmia is listed on NASDAQ
Stockholm (OASM.ST), Frankfurt Stock Exchange (OMAX.GR, ISIN
SE0000722365) and NASDAQ USA (OASM.US).
No comments:
Post a Comment